Cargando…

Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms

BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly being used to treat malignancies. Some patients experience immune-related adverse events (irAEs), which may affect any organ/tissue. IrAEs are occasionally fatal and usually have nonspecific symptoms. We developed a three-step applicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Osawa, Takahiro, Abe, Takashige, Kikuchi, Hiroshi, Matsumoto, Ryuji, Murai, Sachiyo, Nakao, Takafumi, Tanaka, Shinji, Watanabe, Ayu, Shinohara, Nobuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923505/
https://www.ncbi.nlm.nih.gov/pubmed/35290407
http://dx.doi.org/10.1371/journal.pone.0265230
_version_ 1784669690035961856
author Osawa, Takahiro
Abe, Takashige
Kikuchi, Hiroshi
Matsumoto, Ryuji
Murai, Sachiyo
Nakao, Takafumi
Tanaka, Shinji
Watanabe, Ayu
Shinohara, Nobuo
author_facet Osawa, Takahiro
Abe, Takashige
Kikuchi, Hiroshi
Matsumoto, Ryuji
Murai, Sachiyo
Nakao, Takafumi
Tanaka, Shinji
Watanabe, Ayu
Shinohara, Nobuo
author_sort Osawa, Takahiro
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly being used to treat malignancies. Some patients experience immune-related adverse events (irAEs), which may affect any organ/tissue. IrAEs are occasionally fatal and usually have nonspecific symptoms. We developed a three-step application (https://irae-search.com/) to provide healthcare professionals with information on the diagnosis, treatment options, and published reports for 38 categories of irAEs encountered in clinical practice. METHODS: IrAEs reported in ≥5 cases were identified from articles published between October 2018 and August 2020 by searching Japanese (SELIMIC, JAPIC-Q Service, and JMED Plus) and international (MEDLINE, EMBASE, Derwent Drug File) databases. The cases’ symptoms were entered into the application to identify irAEs, which were verified using the reported diagnosis, to evaluate the application’s sensitivity and specificity. RESULTS: Overall, 1209 cases (1067 reports) were analyzed. The three most common categories of irAEs were pituitary or adrenal disorders (14% of cases), skin disorders (13%), and diabetes mellitus (10%). The top three primary diseases were lung cancer (364 cases), melanoma (286 cases), and renal cell carcinoma (218 cases). The average sensitivity was 90.8% (range 44.4%–100.0%) initially, and improved to 94.8% (range 83.3%–100.0%) after incorporating the symptoms reported in published cases into the application’s logic for two irAE categories. The average specificity was 79.3% (range 59.1% [thyroid disorders]–98.2% [arthritis]). CONCLUSION: irAE Search is an easy-to-use application designed to help healthcare professionals identify potential irAEs in ICI-treated patients in a timely manner to facilitate prompt management/treatment. The application showed high sensitivity and moderate-to-high specificity for detecting irAEs.
format Online
Article
Text
id pubmed-8923505
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-89235052022-03-16 Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms Osawa, Takahiro Abe, Takashige Kikuchi, Hiroshi Matsumoto, Ryuji Murai, Sachiyo Nakao, Takafumi Tanaka, Shinji Watanabe, Ayu Shinohara, Nobuo PLoS One Research Article BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly being used to treat malignancies. Some patients experience immune-related adverse events (irAEs), which may affect any organ/tissue. IrAEs are occasionally fatal and usually have nonspecific symptoms. We developed a three-step application (https://irae-search.com/) to provide healthcare professionals with information on the diagnosis, treatment options, and published reports for 38 categories of irAEs encountered in clinical practice. METHODS: IrAEs reported in ≥5 cases were identified from articles published between October 2018 and August 2020 by searching Japanese (SELIMIC, JAPIC-Q Service, and JMED Plus) and international (MEDLINE, EMBASE, Derwent Drug File) databases. The cases’ symptoms were entered into the application to identify irAEs, which were verified using the reported diagnosis, to evaluate the application’s sensitivity and specificity. RESULTS: Overall, 1209 cases (1067 reports) were analyzed. The three most common categories of irAEs were pituitary or adrenal disorders (14% of cases), skin disorders (13%), and diabetes mellitus (10%). The top three primary diseases were lung cancer (364 cases), melanoma (286 cases), and renal cell carcinoma (218 cases). The average sensitivity was 90.8% (range 44.4%–100.0%) initially, and improved to 94.8% (range 83.3%–100.0%) after incorporating the symptoms reported in published cases into the application’s logic for two irAE categories. The average specificity was 79.3% (range 59.1% [thyroid disorders]–98.2% [arthritis]). CONCLUSION: irAE Search is an easy-to-use application designed to help healthcare professionals identify potential irAEs in ICI-treated patients in a timely manner to facilitate prompt management/treatment. The application showed high sensitivity and moderate-to-high specificity for detecting irAEs. Public Library of Science 2022-03-15 /pmc/articles/PMC8923505/ /pubmed/35290407 http://dx.doi.org/10.1371/journal.pone.0265230 Text en © 2022 Osawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Osawa, Takahiro
Abe, Takashige
Kikuchi, Hiroshi
Matsumoto, Ryuji
Murai, Sachiyo
Nakao, Takafumi
Tanaka, Shinji
Watanabe, Ayu
Shinohara, Nobuo
Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
title Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
title_full Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
title_fullStr Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
title_full_unstemmed Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
title_short Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
title_sort validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923505/
https://www.ncbi.nlm.nih.gov/pubmed/35290407
http://dx.doi.org/10.1371/journal.pone.0265230
work_keys_str_mv AT osawatakahiro validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT abetakashige validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT kikuchihiroshi validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT matsumotoryuji validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT muraisachiyo validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT nakaotakafumi validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT tanakashinji validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT watanabeayu validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms
AT shinoharanobuo validationofanonlineapplicationtoidentifypotentialimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitorsbasedonthepatientssymptoms